Defence Therapeutics DTCFF Stock
Defence Therapeutics Price Chart
Defence Therapeutics DTCFF Financial and Trading Overview
| Defence Therapeutics stock price | 1.08 USD |
| Previous Close | 1.95 USD |
| Open | 1.95 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.95 - 1.95 USD |
| 52 Week Range | 1.12 - 4.47 USD |
| Volume | 200 USD |
| Avg. Volume | 36 USD |
| Market Cap | 87.58M USD |
| Beta (5Y Monthly) | 2.262995 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
DTCFF Valuation Measures
| Enterprise Value | 84.01M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 60.987495 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Defence Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.262995 |
| 52-Week Change | 16.16% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.47 USD |
| 52 Week Low | 1.12 USD |
| 50-Day Moving Average | 2.52 USD |
| 200-Day Moving Average | 2.48 USD |
DTCFF Share Statistics
| Avg. Volume (3 month) | 36 USD |
| Avg. Daily Volume (10-Days) | 27 USD |
| Shares Outstanding | 43.68M |
| Float | 41.55M |
| Short Ratio | N/A |
| % Held by Insiders | 5.10% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -174.25% |
| Return on Equity (ttm) | -506.97% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -7212333 USD |
| Diluted EPS (ttm) | -0.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.88M USD |
| Total Cash Per Share (mrq) | 0.07 USD |
| Total Debt (mrq) | 1.64M USD |
| Total Debt/Equity (mrq) | 123.41 USD |
| Current Ratio (mrq) | 17.423 |
| Book Value Per Share (mrq) | 0.032 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6779771 USD |
| Levered Free Cash Flow (ttm) | -4222312 USD |
Profile of Defence Therapeutics
| Country | United States |
| State | BC |
| City | Vancouver |
| Address | 1680 – 200 Burrard Street |
| ZIP | V6C 3L6 |
| Phone | N/A |
| Website | https://defencetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Q&A For Defence Therapeutics Stock
What is a current DTCFF stock price?
Defence Therapeutics DTCFF stock price today per share is 1.08 USD.
How to purchase Defence Therapeutics stock?
You can buy DTCFF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Defence Therapeutics?
The stock symbol or ticker of Defence Therapeutics is DTCFF.
Which industry does the Defence Therapeutics company belong to?
The Defence Therapeutics industry is Biotechnology.
How many shares does Defence Therapeutics have in circulation?
The max supply of Defence Therapeutics shares is 46.72M.
What is Defence Therapeutics Price to Earnings Ratio (PE Ratio)?
Defence Therapeutics PE Ratio is now.
What was Defence Therapeutics earnings per share over the trailing 12 months (TTM)?
Defence Therapeutics EPS is -0.14 USD over the trailing 12 months.
Which sector does the Defence Therapeutics company belong to?
The Defence Therapeutics sector is Healthcare.